You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,118,956


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,118,956
Title:Fusion partners for peptide production
Abstract: The present invention relates to the field of medicine, in particular, to the production of large amounts of a soluble recombinant polypeptide as part of a fusion protein comprising an N-terminal fusion partner linked to the polypeptide of interest.
Inventor(s): Retallack; Diane M. (Poway, CA), Chapman; Adam (San Diego, CA), Bruck; Torben R. (Lakeside, CA), Jin; Hongfan (San Diego, CA)
Assignee: PFENEX INC. (San Diego, CA)
Application Number:14/954,766
Patent Claims:1. A recombinant fusion protein comprising: an N-terminal fusion partner, wherein the N-terminal fusion partner is selected from: P. fluorescens DnaJ-like protein wherein the P. fluorescens DnaJ-like protein has the amino acid sequence set forth as SEQ ID NO: 2; P. fluorescens FklB protein wherein the P. fluorescens FklB protein has the amino acid sequence set forth as SEQ ID NO: 4, 28, 61, or 62; P. fluorescens FrnE protein wherein the P. fluorescens FrnE protein has the amino acid sequence set forth as SEQ ID NO: 3, 63, or 64; P. fluorescens FkbP protein wherein the P. fluorescens FkbP protein has the amino acid sequence set forth as SEQ ID NO: 25; and P. fluorescens EcpD protein wherein the P. fluorescens EcpD protein has the amino acid sequence set forth as SEQ ID NO: 7, 65, 66, or 67; a polypeptide of interest selected from: hPTH1-34, a proinsulin that is processed to insulin or an insulin analog; Glp1; Glp2; IGF-1; Exenatide (SEQ ID NO: 37); Teduglutide (SEQ ID NO: 39); Pramlintide (SEQ ID NO: 40); Ziconotide (SEQ ID NO: 41); Becaplermin (SEQ ID NO: 42); Enfuvirtide (SEQ ID NO: 43); Nesiritide (SEQ ID NO: 44); a N-met-GCSF; GCSF; P. falciparum circumsporozoite protein; and IFN-.beta.; and a linker of 10 to 50 amino acids in length, comprising a cleavage site between the N-terminal fusion partner and the polypeptide of interest.

2. The recombinant fusion protein of claim 1, wherein the polypeptide of interest is a proinsulin, wherein the proinsulin is processed to insulin or an insulin analog, and wherein the proinsulin comprises a C-peptide that has an amino acid sequence selected from: SEQ ID NO: 97; SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100.

3. The recombinant fusion protein of claim 1, wherein the insulin analog is insulin glargine, insulin aspart, lispro, glulisine, detemir, or degludec.

4. The recombinant fusion protein of claim 1, wherein the cleavage site is recognized by a cleavage enzyme in the group consisting of: enterokinase, trypsin, Factor Xa, and furin.

5. The recombinant fusion protein of claim 1, wherein the linker comprises an affinity tag.

6. The recombinant fusion protein of claim 1, wherein the linker has an amino acid sequence selected from: from the N to C terminus, a (G4S).sub.2 spacer sequence (SEQ ID NO: 59), a hexahistidine affinity tag (SEQ ID NO: 242), and a protease cleavage site DDDDK (SEQ ID NO: 13); from the N to C terminus, a (G4S).sub.2 spacer sequence (SEQ ID NO: 59), a hexahistidine affinity tag (SEQ ID NO: 242), and a protease cleavage site RKR; from the N to C terminus, a (G4S).sub.2 spacer sequence (SEQ ID NO: 59), a hexahistidine affinity tag (SEQ ID NO: 242), and a protease cleavage site RRR; from the N to C terminus, a (G4S).sub.2 spacer sequence (SEQ ID NO: 59), a hexahistidine affinity tag (SEQ ID NO: 242), and a protease cleavage site LVPR; and SEQ ID NO: 226.

7. The recombinant fusion protein of claim 1, wherein the polypeptide of interest is hPTH1-34, and wherein the recombinant fusion protein comprises an amino acid sequence selected from: SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47.

8. The recombinant fusion protein of claim 1, wherein the N-terminal fusion partner is P. fluorescens FklB protein, wherein the P. fluorescens FklB protein has the amino acid sequence set forth as SEQ ID NO: 4, 28, 61, or 62, and wherein the polypeptide of interest is hPTH1-34.

9. The recombinant fusion protein of claim 8, wherein the linker further comprises a spacer and an affinity tag.

10. The recombinant fusion protein of claim 9, wherein: a. the spacer is selected from: (G4S).sub.1, (G4S).sub.2, (G4S).sub.3, (G4S).sub.4, and (G4S).sub.5; b. the affinity tag is selected from: a Maltose Binding Protein tag, a Polyhistidine tag, a FLAG tag, a Myc tag, an HA-tag, and a Nus tag; and c. the cleavage site is selected from: an enterokinase cleavage site, a trypsin cleavage site, a chymotrypsin cleavage site, a Factor Xa cleavage site, and a Furin cleavage site.

11. The recombinant fusion protein of claim 1, wherein the N-terminal fusion partner is P. fluorescens FklB protein, wherein the P. fluorescens FklB protein has the amino acid sequence set forth as SEQ ID NO: 4, 28, 61, or 62, and wherein the polypeptide of interest is a proinsulin that is processed to insulin or an insulin analog.

12. The recombinant fusion protein of claim 11, wherein the linker further comprises an affinity tag.

13. The recombinant fusion protein of claim 12, wherein the linker further comprises a spacer.

14. The recombinant fusion protein of claim 13, wherein: a. the spacer selected is from: (G4S).sub.1, (G4S).sub.2, (G4S).sub.3, (G4S).sub.4, and (G4S).sub.5; b. the affinity tag is selected from: a Maltose Binding Protein tag, a Polyhistidine tag, a FLAG tag, a Myc tag, an HA-tag, and a Nus tag; and c. the cleavage site is selected from: an enterokinase cleavage site, a trypsin cleavage site, a chymotrypsin cleavage site, a Factor Xa cleavage site, and a Furin cleavage site.

15. The recombinant fusion protein of claim 14, wherein the polypeptide of interest is a proinsulin that is processed to insulin or an insulin analog, and wherein the recombinant fusion protein comprises an amino acid sequence selected from SEQ ID NOS: 130-153.

16. A method for producing a polypeptide of interest, comprising: (i) culturing a microbial host cell transformed with an expression vector comprising an expression construct, wherein the expression construct comprises a nucleotide sequence encoding the recombinant fusion protein of claim 1; (ii) inducing the host cell of step (i) to express the recombinant fusion protein; (iii) purifying the recombinant fusion protein expressed in the induced host cells of step (ii); and (iv) cleaving the purified recombinant fusion protein of step (iii) by incubation with a cleavage enzyme that recognizes the cleavage site in the linker, to release the polypeptide of interest; thereby obtaining the polypeptide of interest.

17. The method of claim 16, further comprising measuring the expression level of the fusion protein expressed in step (ii), measuring the amount of the recombinant fusion protein purified in step (iii), or measuring the amount of the polypeptide of interest obtained in step (iv) that has been properly released, or a combination thereof.

18. The method of claim 17, wherein the amount of the polypeptide of interest obtained in step (iii) or step (iv) is about 0.1 g/L to about 25 g/L.

19. The method of claim 17, wherein the properly released polypeptide of interest obtained is soluble, intact, or both.

20. An expression vector for expression of the recombinant fusion protein of claim 1, wherein the expression vector comprises a nucleotide sequence encoding the recombinant fusion protein.

Details for Patent 10,118,956

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 06/07/2000 ⤷  Try a Trial 2034-12-01
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 01/19/2001 ⤷  Try a Trial 2034-12-01
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 04/23/2004 ⤷  Try a Trial 2034-12-01
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 10/31/2013 ⤷  Try a Trial 2034-12-01
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 04/20/2000 ⤷  Try a Trial 2034-12-01
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 04/25/2007 ⤷  Try a Trial 2034-12-01
Smith & Nephew, Inc. REGRANEX becaplermin Gel 103691 12/16/1997 ⤷  Try a Trial 2034-12-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.